日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial

利用硼替佐米和索拉非尼靶向miR29b以提高急性髓系白血病患者对地西他滨的敏感性:一项1期剂量递增试验的结果

Handa, Shivani; Koenig, Kristin; Zhao, Qiuhong; Mims, Alice S; Vasu, Sumithira; Garzon, Ramiro; Haque, Tamanna; Benson, Don; Klisovic, Rebecca B; Marcucci, Guido; Walker, Alison R; Bhatnagar, Bhavana

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis

一项多中心 II 期临床试验,研究低剂量皮下注射地西他滨治疗骨髓纤维化的疗效

Lin, Chenyu; Patel, Anand A; Huo, Dezheng; Karrison, Theodore; van Besien, Koen; Godwin, John; Sher, Dorie; Weiner, Howie; Green, Margaret; Wade, James L 3rd; Klisovic, Rebecca; Baer, Maria R; Larson, Richard A; Stock, Wendy; Odenike, Olatoyosi

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

SWOG 1318:一项针对新诊断的费城染色体阴性B细胞急性淋巴细胞白血病老年患者的II期临床试验,研究Blinatumomab治疗后序贯POMP维持治疗的疗效。

Advani, Anjali S; Moseley, Anna; O'Dwyer, Kristen M; Wood, Brent L; Fang, Min; Wieduwilt, Matthew J; Aldoss, Ibrahim; Park, Jae H; Klisovic, Rebecca B; Baer, Maria R; Stock, Wendy; Bhave, Rupali R; Othus, Megan; Harvey, Richard C; Willman, Cheryl L; Litzow, Mark R; Stone, Richard M; Sharon, Elad; Erba, Harry P

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

米哚妥林可降低 FLT3 突变型急性髓系白血病的复发率:Alliance CALGB 10603/RATIFY 试验

Larson, Richard A; Mandrekar, Sumithra J; Huebner, Lucas J; Sanford, Ben L; Laumann, Kristina; Geyer, Susan; Bloomfield, Clara D; Thiede, Christian; Prior, Thomas W; Döhner, Konstanze; Marcucci, Guido; Voso, Maria Teresa; Klisovic, Rebecca B; Galinsky, Ilene; Wei, Andrew H; Sierra, Jorge; Sanz, Miguel A; Brandwein, Joseph M; de Witte, Theo; Niederwieser, Dietger; Appelbaum, Frederick R; Medeiros, Bruno C; Tallman, Martin S; Krauter, Jürgen; Schlenk, Richard F; Ganser, Arnold; Serve, Hubert; Ehninger, Gerhard; Amadori, Sergio; Gathmann, Insa; Döhner, Hartmut; Stone, Richard M

A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia

一项针对复发/难治性B前体细胞急性淋巴细胞白血病患者的tafasitamab(一种人源化、Fc修饰的抗CD19抗体)的2a期单臂开放标签研究。

Klisovic, Rebecca B; Leung, Wing H; Brugger, Wolfram; Dirnberger-Hertweck, Maren; Winderlich, Mark; Ambarkhane, Sumeet V; Jabbour, Elias J

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

2017 年欧洲白血病网络定义的 NPM1/FLT3-ITD 基因型对急性髓系白血病患者的影响

Döhner, Konstanze; Thiede, Christian; Jahn, Nikolaus; Panina, Ekaterina; Gambietz, Agnes; Larson, Richard A; Prior, Thomas W; Marcucci, Guido; Jones, Dan; Krauter, Jürgen; Heuser, Michael; Voso, Maria Teresa; Ottone, Tiziana; Nomdedeu, Josep F; Mandrekar, Sumithra J; Klisovic, Rebecca B; Wei, Andrew H; Sierra, Jorge; Sanz, Miguel A; Brandwein, Joseph M; de Witte, Theo; Jansen, Joop H; Niederwieser, Dietger; Appelbaum, Frederick R; Medeiros, Bruno C; Tallman, Martin S; Schlenk, Richard F; Ganser, Arnold; Serve, Hubert; Ehninger, Gerhard; Amadori, Sergio; Gathmann, Insa; Benner, Axel; Pallaud, Celine; Stone, Richard M; Döhner, Hartmut; Bloomfield, Clara D

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

一项评估来那度胺联合伊达比星和阿糖胞苷化疗治疗复发或难治性急性髓系白血病和高危骨髓增生异常综合征患者的I期研究

Saygin, Caner; Larkin, Karilyn; Blachly, James S; Orwick, Shelley; Ngankeu, Apollinaire; Gregory, Charles T; Phelps, Mitch A; Mani, Shylaja; Walker, Alison; Garzon, Ramiro; Vasu, Sumithira; Walsh, Katherine J; Bhatnagar, Bhavana; Klisovic, Rebecca B; Grever, Michael R; Marcucci, Guido; Byrd, John C; Blum, William; Mims, Alice S

Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML

口服 JAK2/FLT3 抑制剂帕克替尼联合化疗治疗 FLT3-ITD 阳性 AML 的临床前活性和 I 期试点研究

Jae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, Mitch Phelps, Alison R Walker, Alice S Mims, Sumithira Vasu, Gregory Behbehani, James Blachly, William Blum, Rebecca B Klisovic, John C Byrd, Ramiro Garzon, Sharyn D Baker, Bhavana Bhatnagar

Adherence trajectories in oral therapy for chronic myeloid leukemia: Overview of a research protocol

慢性粒细胞白血病口服治疗依从性轨迹:研究方案概述

Yeager, Katherine A; Waldrop-Valverde, Drenna; Paul, Sudeshna; Bruner, Deborah Watkins; Klisovic, Rebecca; Burns, Emily; Mason, Tamara A; Patel, Nisha; Jennings, Bonnie Mowinski

Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study

塞利尼索联合地西他滨治疗急性髓系白血病患者:一项 1 期研究的结果

Bhatnagar, Bhavana; Zhao, Qiuhong; Mims, Alice S; Vasu, Sumithira; Behbehani, Gregory K; Larkin, Karilyn; Blachly, James S; Blum, William; Klisovic, Rebecca B; Ruppert, Amy S; Orwick, Shelley; Oakes, Christopher; Ranganathan, Parvathi; Byrd, John C; Walker, Alison R; Garzon, Ramiro